Jbf Capital, Inc. Arcus Biosciences, Inc. Transaction History

Jbf Capital, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 12, 2019	SELL	$9.74 - $14.5 $55,634 - $82,824	-5,712 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$10.88 - $14.95 $256,082 - $351,878	-23,537 Reduced 80.47%	5,712 $80,000
Q2 2018 Aug 09, 2018	SELL	$12.24 - $17.05 $865,992 - $1.21 Million	-70,751 Reduced 70.75%	29,249 $358,000
Q1 2018 May 11, 2018	BUY	$15.44 - $17.71 $1.54 Million - $1.77 Million	100,000 New	100,000 $1.54 Million

186

49.2M

204K

149K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.06B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Jbf Capital, Inc., based on Form 13F filings with the SEC.

Stay updated on Jbf Capital, Inc. with notifications on news.